Nomograms and risk score models for predicting survival in rectal cancer patients with neoadjuvant therapy

Table 1 Patient demographics

Variable	Primary cohort (n = 155)		Validation cohort (n = 65)
	No. of patients	%	No. of patients	%
Age
Median	60.00		61.00
Range	52.00-66.00		51.00-65.50
BMI
Median	24.13		23.44
Range	21.78-26.50		21.80-25.27
Death
Yes	18	11.6	15	23.1
No	137	88.4	50	76.9
Her-2
1	34	21.9	18	27.7
2	17	11	6	9.2
3	3	1.9	2	3.1
4	1	0.6
5	100	64.5	39	60
BRAF-V600E
1	105	67.7	45	69.2
2	6	3.9
3	1	0.6
4	1	0.6	1	1.5
5	42	27.1	19	29.2
P53
1	11	7.1	2	3.1
2	7	4.5	1	1.5
3	1	0.6	2	3.1
4	15	9.7	7	10.8
5	121	78.1	53	81.5
ASA
1	3	1.9	3	4.6
2	122	78.7	48	73.8
3	30	19.4	14	21.5
Sex
Male	99	63.9	53	81.5
Female	56	36.1	12	18.5

BMI: Body mass index; ASA: American Society of Anesthesiologists; Her-2: 1-, 2+, 3++, 4+++, 5no; BRAF-V600E: 1-, 2+, 3++, 4no; P53: 1-, 2+, 3++, 4++, 5no.